A population-based study of morbidity after pancreatic cancer diagnosis.

Authors

null

Reith Sarkar

University of California, San Diego, La Jolla, CA

Reith Sarkar , Katherine Elaine Fero , Neil Panjwani , Rayna Matsuno , James Don Murphy

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2018 Gastrointestinal Cancers Symposium

Session Type

Poster Session

Session Title

Poster Session B: Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract

Track

Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract

Sub Track

Prevention, Diagnosis, and Screening

Citation

J Clin Oncol 36, 2018 (suppl 4S; abstr 236)

DOI

10.1200/JCO.2018.36.4_suppl.236

Abstract #

236

Poster Bd #

B11

Abstract Disclosures

Similar Posters

Poster

2018 ASCO Quality Care Symposium

Use of a chemotherapy toxicity prediction tool to decrease the risks for hospitalization in the elderly.

Use of a chemotherapy toxicity prediction tool to decrease the risks for hospitalization in the elderly.

First Author: Mintcho Elinov Mintchev

Poster

2018 Gastrointestinal Cancers Symposium

A phase I fixed-dose feasibility study of MK615 and gemcitabine in patients with advanced or metastatic pancreatic cancer.

A phase I fixed-dose feasibility study of MK615 and gemcitabine in patients with advanced or metastatic pancreatic cancer.

First Author: Ichiro Moriyama

Poster

2017 Genitourinary Cancers Symposium

Population-based analysis of treatment toxicity among men with castration-resistant prostate cancer.

Population-based analysis of treatment toxicity among men with castration-resistant prostate cancer.

First Author: Robert Nam

Poster

2017 Gastrointestinal Cancers Symposium

Gemcitabine and S-1 as first-line chemotherapy in patients with metastatic or advanced pancreatic cancer.

Gemcitabine and S-1 as first-line chemotherapy in patients with metastatic or advanced pancreatic cancer.

First Author: Weijia Fang